

# 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge

Jackie Sherrard<sup>1</sup> , Janet Wilson<sup>2</sup>, Gilbert Donders<sup>3</sup>,  
Werner Mendling<sup>4</sup> and Jørgen S Jensen<sup>5</sup> 

## Abstract

Four common pathological conditions are associated with vaginal discharge: bacterial vaginosis, aerobic vaginitis, candidosis, and the sexually transmitted infection, trichomoniasis. Chlamydial or gonococcal cervical infection may result in vaginal discharge. Vaginal discharge may be caused by a range of other physiological and pathological conditions including atrophic vaginitis, desquamative inflammatory vaginitis, cervicitis, and mucoid ectopy. Psychosexual problems may present with recurrent episodes of vaginal discharge and vulval burning. These need to be considered if tests for specific infections are negative. Many of the symptoms and signs are non-specific and a number of women may have other conditions such as vulval dermatoses or allergic and irritant reactions.

## Keywords

Trichomoniasis (*Trichomonas vaginalis*), women, diagnosis, bacterial vaginosis, candida, aerobic vaginitis, vaginal discharge

Date received: 30 May 2018; accepted: 5 June 2018

## Introduction

Four common pathological conditions are associated with vaginal discharge: bacterial vaginosis (BV), aerobic vaginitis (AV), candidosis, and the sexually transmitted infection, trichomoniasis. Chlamydial or gonococcal cervical infection may result in vaginal discharge. Vaginal discharge may be caused by a range of other physiological and pathological conditions including atrophic vaginitis, desquamative inflammatory vaginitis (DIV), cervicitis, and mucoid ectopy. Psychosexual problems may present with recurrent episodes of vaginal discharge and vulval burning. These need to be considered if tests for specific infections are negative. Many of the symptoms and signs are non-specific and a number of women may have other conditions such as vulval dermatoses or allergic and irritant reactions.

---

<sup>1</sup>Department of Genitourinary Medicine, Sexual Health Department, Buckinghamshire Healthcare NHS Trust, Amersham, UK

<sup>2</sup>Department of Genitourinary Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK

<sup>3</sup>Department of Obstetrics and Gynecology, Regional Hospital H Hart Tienen, University Hospital Antwerp

<sup>4</sup>Infektionen in Gynäkologie und Geburtshilfe, Wuppertal, Germany

<sup>5</sup>Research Unit for Reproductive Microbiology, Statens Serum Institut, Copenhagen, Denmark

Lead editor: Jørgen S Jensen

This guideline is an update of the European IUSTI vaginal discharge guideline 2011.

### Corresponding author:

Jackie Sherrard, Department of Genitourinary Medicine, Sexual Health Department, Buckinghamshire Healthcare NHS Trust, Amersham, UK.  
Email: jackiesherrard@doctors.org.uk

## Aetiology and transmission

### BV

BV is the commonest cause of abnormal vaginal discharge in woman of childbearing age but may also be encountered in perimenopausal women.<sup>1,2</sup> In Caucasian women the prevalence is 5–15%; in Black women it is higher at 45–55%. Women who have sex with women (WSW) share similar lactobacillary types, are more likely to have concordant vaginal microbiota (flora) patterns, and are at increased risk for BV.<sup>3</sup>

BV is a dysbiosis of the vaginal microbiota. It is characterised by an overgrowth of predominantly anaerobic organisms (e.g. *Gardnerella vaginalis*, *Prevotella* spp., *Atopobium vaginae*, *Mycoplasma hominis*, *Mobiluncus* spp.) in the vagina leading to a replacement of lactobacilli and an increase in vaginal pH. Bacterial identification using PCR has demonstrated that there are many different, previously uncultivated bacteria present in women with BV including BV-associated bacterium 1, 2, and 3, and *Sneathia* species.<sup>4</sup> Since these bacteria are difficult to culture, the antibiotic susceptibility of many is not known.

BV can arise and remit spontaneously and although not strictly considered a sexually transmitted infection (STI) it is associated with sexual activity. The exact aetiology of BV is still unclear but current evidence suggests that formation of a biofilm with *G. vaginalis* is important in the switch from normal vaginal flora to BV.<sup>5,6</sup>

### AV/DIV

AV presents with a purulent discharge, some degree of atrophy, and vaginitis. Lactobacilli are decreased and pH is elevated, but aerobic microorganisms, like *Escherichia coli*, group B streptococci, and *Staphylococcus aureus* predominate.<sup>7</sup> Mixed infections

are frequent. It is not known whether AV has an infectious origin or whether it is an inflammatory process followed by a dysbiosis. It can cause long-term symptoms with intermittent exacerbations, and recurrences after treatment are common.<sup>8</sup> Atrophic vaginitis in lactating women is probably a variant of AV. More severe forms of AV and DIV are probably the same condition.

### Candidosis

More than 60% of healthy premenopausal women are colonised with candida, with higher rates in pregnancy, and lower rates in children and postmenopausal women without hormonal replacement therapy.<sup>9,10</sup> An estimated 75% of women will experience at least one symptomatic episode during their lifetime and 6–9% will experience chronic recurrent vulvovaginal candidosis (at least four episodes per year). Vulvovaginal candidosis results from an overgrowth of *Candida albicans* in 90% of women (remainder with other species, e.g. *Candida glabrata*).<sup>11,12</sup> Precipitating factors include antibiotic therapy, pregnancy, and endogenous or exogenous immunosuppression (including diabetes mellitus and immunosuppressive medication). In some women, symptoms may occur with a low burden of candida and it is thought this may be due to an allergic or inflammatory response to the yeast.

### Trichomoniasis

*Trichomonas vaginalis* (TV) is a flagellated protozoan, which is a parasite of the genital tract. In adults, it is almost exclusively sexually transmitted. Due to site specificity, infection only follows intravaginal or intraurethral inoculation of the organism. In women urethral infection is present in 90% of episodes, although the urinary tract is the sole site of infection in <5% of cases. The most obvious host response to infection is a local increase in polymorphonuclear leucocytes.

**Table 1.** Symptoms and signs.

Bacterial vaginosis	Aerobic vaginitis	Candidosis	Trichomoniasis
Approximately 50% asymptomatic	10–20% asymptomatic	Approx. 60% women colonised. Minority develop symptoms	10–50% asymptomatic and 5–15% no abnormal signs
Thin white homogenous discharge, coating walls of vagina and vestibule	Purulent discharge	Vaginal discharge may be curdy (non-offensive)	Offensive vaginal discharge in up to 70% – frothy and yellow in 10–30%
Offensive fishy odour	Vulval burning or stinging	Vulval soreness/itching and erythema	Vulval itching/irritation and erythema
Absence of vaginitis	Superficial dyspareunia Vaginal erythema and oedema Vaginal ulceration	Vulval fissuring Superficial dyspareunia  Satellite skin lesions Vulval oedema	Dysuria Rarely low abdominal discomfort  Vaginitis Approx. 2% ‘strawberry’ cervix visible to naked eye.

## Clinical features

There are recognised symptoms and signs (Table 1). The diagnosis of both BV and candidosis is syndromic, i.e. based on clinical symptoms and signs supported by laboratory test findings, which in themselves vary in specificity and sensitivity. The classical features of TV are frequently absent or non-specific.<sup>13,14</sup>

## Complications

Women with BV are at increased risk of acquiring STIs. They have a two-fold increased risk of HIV acquisition,<sup>15</sup> 1.5–2-fold risk of Chlamydia<sup>16</sup> and gonorrhoea,<sup>16</sup> a nine-fold risk of TV,<sup>17</sup> and a two-fold risk of herpes simplex virus type 2 (HSV-2)<sup>18</sup> compared to women without BV. HIV-positive women with BV have a three-fold risk of transmitting HIV.<sup>19</sup> Monthly prophylaxis with metronidazole reduces the incidence of STIs by almost 50%.<sup>20</sup> The BV-associated bacteria are probably also implicated in the aetiology of pelvic inflammatory disease (PID). A prospective study of women with clinically-suspected PID reported significant correlations between the presence of BV-associated bacteria and the presence of endometritis and recurrent PID.<sup>21</sup>

There is an association with BV and post-hysterectomy vaginal cuff infection,<sup>22,23</sup> post-abortion endometritis,<sup>24,25</sup> and an increased risk of spontaneous miscarriage and preterm birth.<sup>26,27</sup> Symptomatic pregnant women with BV should be treated in the usual way but the latest Cochrane review concludes there is insufficient evidence to recommend routine screening and treating all pregnant women for asymptomatic BV to prevent preterm birth.<sup>28</sup>

Multiple reports support an epidemiological association between HIV and trichomoniasis. There is growing evidence that trichomonal infection enhances HIV transmission<sup>29–32</sup> and there may be an increased risk of TV infection in those that are HIV-positive.<sup>33</sup>

Trichomoniasis is associated with adverse pregnancy outcomes.<sup>34,35</sup> The literature on metronidazole treatment during pregnancy and preterm birth is not conclusive. The most recent Cochrane review found that metronidazole is effective against trichomoniasis when taken by women and their partners during pregnancy, but it may harm the baby due to early birth.<sup>36</sup> Screening of asymptomatic individuals for TV infection is therefore not currently recommended.

Although only recently described, moderate/severe AV is associated with an increasing number of co-infections and complications.<sup>37</sup> An increased risk of preterm delivery and chorioamnionitis in women with first trimester AV has been described.<sup>38</sup>

Several studies in the last decade have shown a decrease in preterm birth, if vaginal candida colonisation or infection had been treated with clotrimazole.<sup>39</sup> In a study by Holzer et al.<sup>40</sup> women who were colonised with candida spp. during the second trimester of pregnancy had higher rates of preterm birth and lower neonatal birthweight than those who were colonised during the first trimester of their pregnancy. According to old studies the vaginal treatment of an asymptomatic candida colonisation during the last six weeks of pregnancy reduces the candida colonisation of the newborn during vaginal delivery and thus reduces oral thrush and napkin dermatitis of the baby during the first four weeks of life.<sup>41</sup> Modern studies are urgently needed to confirm these findings.

## Diagnosis

Women presenting with abnormal vulval or vaginal symptoms should be tested to ensure that appropriate treatment is given.<sup>40,42–44</sup> If this is not possible, then examination and testing should definitely be performed in the following situations:

- Severe or recurrent symptoms
- Failure of vaginal discharge to respond to empirical treatment
- Symptoms in pregnancy
- Finding of TV on cervical cytology
- Diagnosis of TV in sexual partner

Asymptomatic women do not require testing for BV, AV, or candida. Testing asymptomatic women for TV should be guided by local prevalence data.

The definitive diagnosis of each infection is based upon clinical symptoms, examination, pH and microscopic findings of the vaginal secretions, and for TV additionally by laboratory tests. A sample of the discharge is removed from the vaginal wall with a swab. This can be performed by the clinician or be self-collected by the woman.<sup>45</sup> The type of swab is not important. An elevated pH (>4.5) is suggestive of BV or trichomoniasis and is almost always normal in candida infections. Direct microscopy should be done immediately, if available.

## BV

*Gram-stained microscopy* is the reference method for diagnosing BV.

- A. Nugent score<sup>46</sup> – This is used as a gold standard for studies and relies upon estimating the relative proportions of bacterial morphotypes on a Gram-stained vaginal smear to give a score between 0

and 10. A score of <4 is normal, 4–6 is intermediate, and >6 is BV. However, it does not take bacterial morphotypes other than those associated with BV into account. The clinical implications of ‘intermediate flora’ are unclear but they are associated with complications.<sup>47</sup>

**B. Hay–Ison criteria<sup>48</sup>** – These are also based on the findings on a Gram-stained smear but are easier and quicker to use in clinical practice and do include non-BV-associated bacteria.

Grade 0: Not related to BV, epithelial cells only, no lactobacilli, indicates recent antibiotics

Grade 1: (Normal): Lactobacillus morphotypes predominate

Grade 2: (Intermediate): Mixed flora with some lactobacilli present, but *Gardnerella* or *Mobiluncus* morphotypes also present

Grade 3 (BV): Predominantly *Gardnerella* and/or *Mobiluncus* morphotypes, clue cells. Few or absent Lactobacilli.

Grade 4: Not related to BV, Gram-positive cocci only, no lactobacilli (AV flora)

#### *Clinical criteria for diagnosis of BV (Amsel)<sup>49</sup>*

The presence of three of the four criteria is required; as three are clinical criteria it is possible to make a diagnosis of BV without microscopy or the use of a microbiology laboratory. Compared to Gram-stained microscopy, the presence of three of the four clinical criteria has a sensitivity of 60–72% for the diagnosis of BV.<sup>50,51</sup>

1. Homogeneous grey-white discharge
2. pH of vaginal fluid > 4.5 (measured using narrow gauge pH paper)
3. Fishy odour (if not recognisable, use few drops of 10% KOH)
4. Clue cells present on wet mount microscopy (>20% of all epithelial cells)

#### *Other methods of diagnosing BV*

Commercial tests for BV are also available. OSOM BV Blue (Sekisui Diagnostics, Framingham, MA, USA) is a point-of-care test which measures sialidase levels and has sensitivity of 91.7% compared to microscopy.<sup>52</sup> The BD MAX<sup>TM</sup> Vaginal Panel (Becton, Dickinson and company, Franklin Lakes, NJ, USA) is a microbiome-based, nucleic acid amplification assay that detects BV, TV, and several candida species. The manufacturer insert quotes a sensitivity of 90.7% for the diagnosis of BV.<sup>53</sup>

**The Guidelines Group recommends that the current best test to diagnose BV in women is microscopy using the Hay–Ison Criteria.**

**Table 2.** Abbreviated template for assessing the aerobic vaginitis score.<sup>9</sup>

	Enter score
Background flora	
Unremarkable	0
Small coliforms	1
Cocci or chains	2
Lactobacillary grade	
Predominant lactobacilli	0
Reduced lactobacilli	1
No lactobacilli	2
Number of leucocytes	
<10/high-powered field	0
≤10/epithelial cells	1
>10/epithelial cells	2
Toxic leucocyte proportion	
None or sporadic	0
≤50% leucocytes	1
>50% leucocytes	2
Parabasal cells proportion	
None	0
≤10% epithelial cells	1
>10% epithelial cells	2

**Strength of recommendation: Grade 1, quality of evidence: Grade A.**

## AV

### *Microscopy.*

- The gold standard for diagnosis is wet mount microscopy.<sup>54</sup> The AV score combines information about bacterial flora, epithelial disruption, and inflammation creating a score from 0 to 10: 0–2 (no AV), 3–4 (mild AV), 5–6 (moderate AV), or 7–10 (severe AV) (Table 2).

**Cultures.** Although most women with AV have positive cultures for aerobic bacteria such as *Streptococcus agalactiae*, *S. aureus*, *E. coli*, a positive vaginal culture does not indicate the woman has AV and is not recommended for diagnosis. However, culture with antimicrobial susceptibility testing may aid in treatment.

**Molecular detection.** Tests based on molecular biology are being developed which correlate well with moderate-to-severe AV compared with microscopy but need confirmation in larger trials assessing sensitivity and specificity.<sup>55</sup>

**The Guidelines Group recommends that the current best test to diagnose AV in women is microscopy.**

**Strength of recommendation: Grade 2, quality of evidence: Grade B.**

## Candidosis

### Microscopy.

- Budding cells (and a positive candida culture) can exist in asymptomatic, colonised women or in women with candidosis. The diagnosis should be based on a combination of the clinical signs and microscopic findings. Pseudohyphae/mycelia are evidence of candidosis.<sup>55–58</sup>
- Yeasts or pseudohyphae on wet mount microscopy with either saline or 10–20% KOH solution (40–60% sensitivity) of vaginal discharge.
- Yeasts or pseudohyphae on Gram stain (up to 65% sensitivity) of vaginal discharge.

### Culture.

- Vaginal culture positive for a candida species. If possible this should be delineated as *C. albicans* or non-*albicans*. If directly inoculated on to a Sabouraud's plate results should be reported as light, medium, or heavy growth as this correlates with specificity.
- As a high number of women carry candida asymptotically, the significance of light and medium growths should be interpreted with caution.
- Repeated culture of the same species of non-*albicans* Candida (usually *C. glabrata*) indicates reduced antifungal susceptibility to azoles.

**The Guidelines Group recommends that the current best test to diagnose candida in women is microscopy.**

**Strength of recommendation: Grade 1, quality of evidence: Grade B.**

## Trichomoniasis

**Microscopy.** Direct observation of the organism by wet mount microscopy (normal saline) or acridine orange-stained slide from the posterior vaginal fornix. The wet preparation should be read within 10 min of collection, as the trichomonads quickly lose motility and will be more difficult to identify.<sup>59</sup> The sensitivity is highest in women presenting with vaginal discharge. However, the sensitivity is reported to be as low as 45–60%<sup>60–62</sup> so a negative result should be interpreted with caution. The specificity with trained personnel is high.

**Point-of-care tests.** A number of point-of-care tests that have the advantages of microscopy have been described. The OSOM Trichomonas Rapid Test (Sekisui Diagnostics, Framingham, MA, USA) has demonstrated a sensitivity of 80–94% and a specificity greater than 95%.<sup>63,64</sup> This test requires no instrumentation and provides a result within 30 min and is a suitable alternative to culture or molecular testing. Although these tests are more sensitive than vaginal wet mount microscopy, false positives might occur, especially in populations with a low prevalence of

disease, so consideration should be given to confirming positives in that situation.

**Culture.** Culture of TV has a higher sensitivity compared to microscopy but is not widely available. A commercially available culture system (InPouch TV; BioMed Diagnostics, White City, OR, USA), offers many advantages over previous culture media such as Diamond's medium.<sup>65–67</sup> Once inoculated the pouches can be transferred to the laboratory for incubation and the entire pouch read microscopically each day for five days, negating the need to prepare wet preparations every day that only sample a portion of the culture medium.

**Molecular detection.** Nucleic acid amplification tests (NAATs) offer the highest sensitivity for the detection of TV in comparison to both microscopy and culture.<sup>68,69</sup> They should be the test of choice where resources allow. NAATs can detect TV in vaginal or endocervical swabs and in urine samples from women with sensitivities of 88–97% and specificities of 98–99%, depending on the specimen and reference standard.<sup>70–73</sup>

**The Guidelines Group recommends that the current best tests to diagnose TV in women are NAATs.**

**Strength of recommendation: Grade 1, quality of evidence: Grade A.**

## Management

### BV

It should be explained that the cause is unclear and that although there is increasing evidence of an association with sexual activity, and of sexual transmissibility, it is not yet proven to be an STI.

#### *Indications for treatment of BV:*

- Symptoms
- Positive direct microscopy with/without symptoms in some pregnant women (those with a history of prior idiopathic preterm birth or second trimester loss)
- BV in women undergoing gynaecological surgical or invasive diagnostic procedures

Optional: positive direct microscopy in women without symptoms. They may report a beneficial change in their discharge following treatment.

#### *Recommended regimens for BV:*

- Metronidazole 400–500 mg orally twice daily for 5–7 days
- or

- Intravaginal metronidazole gel (0.75%) once daily for five days  
or
- Intravaginal clindamycin cream (2%) once daily for seven days

*Alternative regimens for BV:*

- Metronidazole 2 g orally in a single dose  
or
- Tinidazole 2 g orally in a single dose  
or
- Tinidazole 1 g orally for five days  
or
- Clindamycin 300 mg orally twice daily for seven days  
or
- Dequalinium chloride 10 mg vaginal tablet one daily for six days

For BV, single dose therapies have lower cure rates than prolonged treatment. Oral metronidazole for seven days has a significantly higher cure rate than single dose treatment (88% versus 54%<sup>74</sup> and 82% versus 62%<sup>75</sup> at 3–4 weeks after completion of therapy). Fourteen days of oral metronidazole compared with seven days showed improved cure initially but there was no difference in cure rates 21 days after completion of therapy.<sup>76</sup> A systematic review of trials comparing clindamycin versus metronidazole concluded they have equal efficacy, whether oral or vaginal formulations, both after one week (combined RR 1.01, 95% CI 0.69–1.46) and after one month (combined RR 0.91, 95% CI 0.70–1.18). Roughly, 58–88% will be cured after five days treatment with metronidazole or clindamycin. However, in terms of side effects, in most studies clindamycin tended to have fewer adverse effects than metronidazole (RR 0.75, 95% CI 0.56–1.02). Combining seven days of oral metronidazole with vaginal clindamycin cream did not improve the cure rate compared with seven days oral metronidazole with placebo.<sup>77</sup> Vaginal dequalinium seems to have similar cure rates to vaginal clindamycin cream.<sup>78</sup> The effectiveness of metronidazole and clindamycin is the same, but the cost of oral metronidazole is significantly less than vaginal metronidazole which is cheaper than clindamycin vaginal cream, with dequalinium being the most expensive. Oral metronidazole has more side effects than the other treatments but post-treatment symptomatic candida is more common with intravaginal treatments.

Clindamycin cream as well as metronidazole gel contain mineral oils that are known to diminish the strength of condoms. Therefore, use of barrier contraception is not considered safe during the treatment with any of these vaginal products.

**The Guidelines Group recommends that 5–7 days of topical or oral metronidazole or seven days of intravaginal clindamycin can be considered first line for uncomplicated BV in women depending on personal choice and circumstances.** Cost-effectiveness of the recommended regimens should be considered when adapting the guideline for local use.

**Strength of recommendation: Grade 1, quality of evidence: Grade A.**

### *Recurrent BV*

A longitudinal study of women, following treatment of BV with oral metronidazole for seven days, reported BV recurrence rates of 23% at one month, 43% at three months, and 58% at 12 months.<sup>79</sup> BV is associated with smoking and vaginal douching<sup>80</sup> but there is no evidence that stopping these reduces BV. Studies of consistent condom use have shown a 50% reduction in BV incidence; the combined oral contraceptive pill is associated with a 16% reduction and progestogen depot injections/implants are associated with a 19% reduction in BV incidence.<sup>81</sup> Small studies have reported an increased incidence of BV with the copper intrauterine contraceptive device but it is not known what effect, if any, progestogen-containing levonorgestrel intrauterine systems have on BV incidence. Recurrence of BV is associated with a new or multiple male partners and having had a female partner.

A number of trials have evaluated intravaginal and oral therapies to reduce BV recurrences.

**Intravaginal metronidazole.** A placebo-controlled trial using twice-weekly metronidazole vaginal gel or placebo for 16 weeks reported a significant reduction in BV recurrence. The relative risk at 16 and 28 weeks was RR 0.43 (95% CI 0.25–0.73) and RR 0.68 (95% CI 0.49–0.93) with 70 and 39%, and 34 and 18% of women being BV free at 16 weeks and 28 weeks, respectively. Episodes of candidosis were more common with metronidazole gel.<sup>82</sup> Another placebo-controlled trial assessed vaginal pessaries containing metronidazole 750 mg plus miconazole 200 mg with matched placebo for five nights per month for 12 months. The women were evaluated every two months and the proportion of visits with BV compared to placebo were 21.2 and 32.5%; RR 0.65 (95% CI 0.48–0.87). There was no increase in candidosis with the intervention.<sup>83</sup>

**Oral metronidazole.** A placebo-controlled trial assessed the effect of monthly oral treatment (metronidazole 2 g plus fluconazole 150 mg) versus placebo for 12 months: the intervention reduced the incidence of BV (hazard ratio 0.55 [95% CI 0.49–0.63]).<sup>84</sup>

**Intravaginal lactate gel.** In a small placebo-controlled trial of intravaginal lactate gel 5 ml used for three days after menses for six months, 88% of women using the lactate gel were BV free compared with 10% using placebo.<sup>85</sup>

**Probiotics.** In a systematic review of probiotics for the treatment of BV, the authors concluded that the results do not provide sufficient evidence for or against recommending probiotics for the treatment of BV.<sup>86</sup> A subsequent meta-analysis concluded probiotic interventions were effective for treatment and prevention of BV but the quality of the studies varied.<sup>87</sup> More good quality research is needed to strengthen the body of evidence needed for application by clinicians.

**The Guidelines Group recommends that the current best treatment for persistent and recurrent BV in women is intravaginal metronidazole.**

**Strength of recommendation: Grade 2, quality of evidence: Grade B.**

## AV/DIV

*Indications for treatment of AV/DIV:*

In one study, 5% of women presenting with vaginal discharge had AV scores of 5 and over.<sup>8</sup> However, these were a very heterogeneous group and specific pathologies such as atrophic change, lichen planus, and lichen sclerosus should be identified and treated appropriately.

*Recommended regimens for AV:*

- Two per cent clindamycin cream 5 g intravaginally for 7–21 days<sup>8,88</sup>
- Combination use of intravaginal clindamycin and intravaginal steroids,<sup>88</sup> e.g. hydrocortisone 300–500 mg intravaginally for 7–21 days or Predfoam enema applied intravaginally (off-label use) for more severe cases
- In cases with a significant atrophy component, local oestrogens can be added

Clindamycin is active against staphylococci and streptococci as well as anaerobes. Other antimicrobials which are used with success in AV include kanamycin ovules or moxifloxacin.

**The Guidelines Group recommends that the current best treatment for uncomplicated AV in women is clindamycin cream.**

**Strength of recommendation: Grade 2, quality of evidence: Grade C.**

## Vaginal candidosis

*Indications for therapy of candidosis:*

- Symptomatic women found to have candida on either microscopy or culture.

Asymptomatic women do not require treatment

Asymptomatic male partners do not require treatment

*Recommended regimens for vaginal candidosis:*<sup>9,89,90</sup>

Oral preparations include

- Fluconazole 150 mg as a single dose
- Itraconazole 200 mg twice daily for one day

Intravaginal treatments include

- Clotrimazole vaginal tablet 500 mg as single dose or 200 mg once daily for three days
- Miconazole vaginal ovule 1200 mg as a single dose or 400 mg once daily for three days
- Econazole vaginal pessary 150 mg as a single dose

Treatment with azoles results in relief of symptoms and negative cultures among 80–90% of patients after treatment is completed, whether administered orally or intravaginally. Only topical preparations should be used during pregnancy. Overall, standard single-dose treatments are as effective as longer courses. In a severely symptomatic attack there is proven to be better symptomatic benefit in repeating fluconazole 150 mg after three days.<sup>91</sup> This does not affect relapse rates.

There are a number of other intravaginal preparations available which are all either azoles, of limited availability, e.g. nystatin, or unlicensed. There are limited data to suggest that vulval treatment maybe of added benefit to intravaginal treatment.<sup>92</sup> Where itch is a significant symptom a hydrocortisone-containing topical preparation may provide more rapid symptomatic relief. Any benefit may be from the emollient effect. If oral antifungals are used, then a moisturising cream is cheaper and may be less likely to give an irritant reaction.

**The Guidelines Group recommends that the current best treatment for uncomplicated candida in women is a single-dose azole (oral or vaginal).**

**Strength of recommendation: Grade 1, quality of evidence: Grade A.**

## Recurrent candidosis

Defined as four or more symptomatic episodes per year<sup>93,94</sup>

- Document frequency, establish diagnosis and confirm by culture: all such women should have at least one speciated culture.

- Exclude risk factors (e.g. diabetes, underlying immunodeficiency, corticosteroid use, frequent antibiotic use).
- Consider other diagnoses – vulval dermatitis/eczema/ vestibulodynia are common either coexisting or as a differential diagnosis.

Maintenance therapy needs to be given frequently enough to prevent vaginal regrowth, but the optimal dosing interval is not clear. There are differing opinions on how aggressive maintenance therapy should be – weekly or monthly treatments<sup>93,95</sup> and comparative trials have not been undertaken. The long-term antifungal regimen aims to prevent two essential pathogenetic mechanisms: increased risk of recolonisation and increased risk of transformation to a symptomatic state primarily as a function of pathologic host intolerance of the candida.<sup>96</sup>

Current recommendations are for an initial intensive regimen of fluconazole 150–200 mg daily for three days to attempt mycologic remission before initiating a maintenance regimen. Published maintenance regimens include oral fluconazole (i.e. 100, 150, or 200 mg dose) weekly for six months<sup>93</sup> or 200 mg fluconazole weekly for two months, followed by 200 mg biweekly for four months, and 200 mg monthly for six months, according to the individual response to therapy.<sup>95</sup> If these regimens are not feasible, topical treatments used intermittently can also be considered.

Treatment of persistent vaginal yeast infection due to species other than *C. albicans* is particularly challenging.<sup>97</sup>

General advice includes the use of a vulval moisturiser applied to dry skin and washed off as a soap substitute. Ovulation suppressing progesterone contraception, e.g. medroxyprogesterone acetate (Depo Provera), norgestrel, or desogestrel, may have some benefits in particular women but the evidence for this is poor.<sup>98</sup>

**The Guidelines Group recommends that the current best treatment for persistent and recurrent candida in women is a three-day induction course of an azole followed by long-term maintenance suppressive regimen for at least six months.**

**Strength of recommendation: Grade 2, quality of evidence: Grade C.**

## TV

As TV is a sexually transmitted organism, screening for coexistent STIs should be undertaken. Sexual abstinence should be advised until treatment of all partners is completed.

*Indications for therapy of TV:*

- Positive test for TV regardless of symptoms
- Epidemiological treatment of sexual partners

*Recommended regimens for TV:*<sup>99–101</sup>

First choice:

- Metronidazole 400–500 mg orally twice daily for 5–7 days  
or
- Metronidazole 2 g orally in a single dose  
or
- Tinidazole 2 g orally in a single dose

The nitroimidazoles are the only class of drugs useful for the oral or parenteral therapy of trichomoniasis and most strains are highly susceptible. Due to high rates of infection of the urethra and paraurethral glands in women systemic chemotherapy should be given to effect a cure. The use of metronidazole gel is not recommended. Oral single dose treatment is associated with more frequent side effects than longer treatment and a recent meta-analysis<sup>99</sup> indicated higher treatment failure for single-dose compared to multi-dose. In patients with true metronidazole allergy, desensitisation has been used.<sup>102,103</sup>

Patients should be advised not to take alcohol for the duration of treatment and for at least 48 h (72 h for tinidazole) afterwards because of the possibility of a disulfiram-like (Antabuse® effect) CSL Biotherapies, New Zealand reaction.

**The Guidelines Group recommends that the current best treatment for uncomplicated TV in women are nitroimidazoles (metronidazole or tinidazole).**

**Strength of recommendation: Grade 1, quality of evidence: Grade A.**

*Persistent TV.* Persistent or recurrent TV is due to inadequate therapy,<sup>104</sup> reinfection, or resistance. Check for compliance and exclude vomiting of metronidazole and exclude the possibility of reinfection from new or untreated partners.

*Treatment protocol for non-response to standard TV therapy* (having excluded reinfection and non-adherence)

1. Repeat course of seven-day standard therapy
  - Metronidazole 400–500 mg twice daily for seven days – in those who failed to respond to a first course of treatment, 40% responded to a repeat course of standard treatment.<sup>104</sup>
2. Higher-dose course of nitroimidazole
  - Metronidazole or tinidazole 2 g daily for 5–7 days<sup>105</sup>

- Metronidazole 800 mg three times daily for seven days – in those who failed to respond to a second course of treatment, 70% responded to a higher-dose course of metronidazole.<sup>104</sup>

For those failing this regimen, resistance testing should be performed if available as improved outcomes were reported with a treatment protocol guided by the results of a resistance test.<sup>104</sup> If resistance testing is not available high-dose tinidazole regimens are recommended as in the above study; 65% of women with clinical treatment failure did not have tinidazole-resistant isolates and 83% of those receiving the recommended high-dose treatment were cured compared with 57% of women receiving a lower-than-recommended dose.<sup>105</sup> Tinidazole has a longer serum half-life, good tissue penetration, a better side effect profile, and lower levels of resistance than metronidazole so should be used when infections have not responded to metronidazole even though it is more expensive.

### 3. Very high-dose course of tinidazole

- Tinidazole 1 g twice or three times daily, or 2 g twice daily for 14 days ± intravaginal tinidazole 500 mg twice daily for 14 days<sup>105–107</sup> – in those who had failed other treatments 92 and 90% responded to a very high-dose course of tinidazole.

If very high-dose tinidazole has been unsuccessful it is difficult to recommend specific further treatment. There are anecdotal reports of treatment success with a number of other treatments. The reports are based on success in one or two women who had usually received a wide variety of prior treatments. Consequently, for each successful anecdote there are a number of reports of treatment failure.

**The Guidelines Group recommends that the current best treatment for persistent and recurrent TV in women is repeated course of nitroimidazole at a higher dose.**

**Strength of recommendation: Grade B, quality of evidence: Grade B.**

## Management during pregnancy and breast feeding

A recent retrospective, case-control study found an association between the use of a number of antibiotics prescribed in the first trimester of pregnancy and spontaneous abortion. Statistically significant associations were found with metronidazole. Clindamycin was not tested in this study. Sexually transmitted genital infections themselves can cause pregnancy loss so failure to treat them effectively may also result in spontaneous

abortion. The associations found might result from women being prescribed the antibiotics for genital infections with the increased risk of pregnancy loss being due to the infections rather than the antibiotics, i.e. confounding by indication.<sup>108</sup>

Meta-analyses have concluded that there is no evidence of teratogenicity from the use of metronidazole in women during the first trimester of pregnancy.<sup>109–112</sup> Metronidazole can be used in all stages of pregnancy and during breast feeding. Symptomatic women with TV and BV should be treated at diagnosis, although some clinicians have preferred to defer treatment until the second trimester. The British National Formulary advises against high-dose regimens in pregnancy. Metronidazole enters breast milk and may affect its taste. The manufacturers recommend avoiding high doses if breastfeeding or if using a single dose of metronidazole, breastfeeding should be discontinued for 12–24 h to reduce infant exposure.

Tinidazole is pregnancy category C (animal studies have demonstrated an adverse event, and no adequate, well-controlled studies in pregnant women have been conducted), and its safety in pregnant women has not been well evaluated. The manufacturer states that the use of tinidazole in the first trimester is contraindicated.

Topical azoles can be used at any stage of pregnancy for treatment of symptomatic candidosis. Oral fluconazole is associated with early abortions and Fallot tetralogy, if administered in the first weeks of pregnancy.<sup>113,114</sup> There appears to be less risk with oral preparations after the first trimester.

**The Guidelines Group recommends that the current best treatment for TV in pregnant women is metronidazole.**

**Strength of recommendation: Grade 1, quality of evidence: Grade A.**

**The Guidelines Group recommends that the current best treatment for BV in pregnant women is clindamycin.**

**Strength of recommendation: Grade 2, quality of evidence: Grade C.**

**The Guidelines Group recommends that the current best treatment for candida in pregnant women are topical azole preparations.**

**Strength of recommendation: Grade 1, quality of evidence: Grade B.**

## Management of sexual partners

### BV

A systematic review assessing the effectiveness of antibiotic treatment for male sexual partners of women treated for BV concluded that antibiotic treatment does not lead to a lower recurrence rate in the women.<sup>115</sup> Routine screening and treatment of male partners is therefore not indicated.

In WSW, regular female partners frequently have concordant vaginal microbiota so if one has BV the partner is more likely to also have BV. It is thought this is from sexual behaviours that transfer vaginal secretions between them.<sup>3</sup> If a WSW is found to have BV, and she has a regular female partner, it would be reasonable to suggest that her partner be checked for BV and be treated if positive although there is no evidence that this will reduce BV recurrences.

**The Guidelines Group recommends that the current advice for women diagnosed with BV is that male sexual partners do not require treatment. Female partners may be treated if they have BV.**

**Strength of recommendation: Grade 2, quality of evidence: Grade B.**

### Candidosis and AV

Routine screening and treatment of male partner(s) is not indicated.<sup>116,117</sup>

**The Guidelines Group recommends that the current advice for women diagnosed with candidosis or is that sexual partners, do not require treatment.**

**Strength of recommendation: Grade 1, quality of evidence: Grade B.**

### Trichomoniasis

Current sexual partners should be screened for STIs and treated for TV regardless of the results of their tests.<sup>118,119</sup> Patients should be instructed to avoid sex until they and their sex partners are cured (i.e. when therapy has been completed and patient and partner[s] are asymptomatic).

**The Guidelines Group recommends that the current advice for women diagnosed with TV, is that their sexual partners should be treated for TV.**

**Strength of recommendation: Grade 1, quality of evidence: Grade A.**

## Follow-up

### BV

Only in women with persistent symptoms. If treatment is prescribed in pregnancy to reduce the risk of preterm birth, a repeat test should be made after one month and further treatment offered if BV has recurred.

### AV

Women with persistent or recurrent symptoms.

### Candida

Only in women with persistent or recurrent symptoms. Consider other diagnoses, e.g. vulval dermatitis.

### Trichomoniasis

Follow-up is unnecessary for men and women who become asymptomatic after treatment or who are initially asymptomatic. Tests of cure are only recommended if the patient remains symptomatic following treatment or if symptoms recur.

## Acknowledgements

The authors wish to acknowledge the following individuals for their helpful comments:

Prof Harald Moi

Dr Raj Patel

Dr Keith Radcliffe

Prof Jonathan Ross

Dr Andy Winter

Composition of editorial board (see <http://www.iusti.org/regions/Europe/pdf/2017/EditorialBoardSept2017.pdf>)

List of contributing organisations (see [www.iusti.org/regions/Europe/euroguidelines.htm](http://www.iusti.org/regions/Europe/euroguidelines.htm))

## Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Proposed review date: 2023

## ORCID iD

Jackie Sherrard  <http://orcid.org/0000-0002-1310-0372>

Jørgen S Jensen  <http://orcid.org/0000-0002-7464-7435>

## References

1. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. *Sex Transm Dis* 2007; 34: 864–869.
2. Lamont RF, Morgan DJ, Wilden SD, et al. Prevalence of bacterial vaginosis in women attending one of three general practices for routine cervical cytology. *Int J STD AIDS* 2000; 11: 495–498.
3. Marrazzo JM, Koutsky LA, Eschenbach DA, et al. Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. *J Infect Dis* 2002; 185: 1307–1313.
4. Fredricks DN, Fiedler TL and Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. *N Engl J Med* 2005; 353: 1899–1911.
5. Schwebke JR, Muzny CA and Josey WE. Role of *Gardnerella vaginalis* in the pathogenesis of bacterial vaginosis: a conceptual model. *J Infect Dis* 2014; 209: 338–343.

6. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. *Obstet Gynecol* 2005; 106: 1013–1023.
7. Donders GG. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. *BJOG* 2002; 109: 1–10.
8. Mason MJ and Winter AJ. How to diagnose and treat aerobic and desquamative inflammatory vaginitis. *Sex Transm Infect* 2017; 93: 8–10.
9. Lindner JG, Plantema FH and Hoogkamp K. Quantitative studies of the vaginal flora of healthy women and of obstetric and gynaecological patients. *J Med Microbiol* 1978; 11: 233–241.
10. Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidosis. *Ann N Y Acad Sci* 1988; 544: 547–557.
11. Fidel PL Jr, Barousse M, Espinosa T, et al. An intravaginal live *Candida* challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. *Infect Immun* 2004; 72: 2939–2946.
12. Holland J, Young ML, Lee O, et al. Vulvovaginal carriage of yeasts other than *Candida albicans*. *Sex Transm Infect* 2003; 79: 249–250.
13. Wolner-Hanssen P, Kreiger JN, Stevens CE, et al. Clinical manifestations of vaginal trichomoniasis. *JAMA* 1989; 264: 571–576.
14. Fouts AC and Kraus SJ. *Trichomonas vaginalis*: re-evaluation of its clinical presentation and laboratory diagnosis. *J Infect Dis* 1980; 141: 137–143.
15. Atashili J, Poole C, Ndumbe PM, et al. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. *AIDS* 2008; 22: 1493–1501.
16. Brotman RM, Klebanoff MA, Tonia R, et al. Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. *J Infect Dis* 2010; 202: 1907–1915.
17. Rathod SD, Krupp K, Klausner JD, et al. Bacterial vaginosis and risk for *Trichomonas vaginalis* infection: a longitudinal analysis. *Sex Transm Dis* 2011; 38: 882–886.
18. Chernes TL, Meyn LA, Krohn MA, et al. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. *Clin Infect Dis* 2003; 37: 319–325.
19. Cohen CR, Lingappa JR, Baeten JM, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. *PLoS Med* 2012; 9: e1001251.
20. Balkus JE, Manhart LE, Lee J, et al. Periodic presumptive treatment for vaginal infections may reduce the incidence of sexually transmitted bacterial infections. *J Infect Dis* 2016; 213: 1932–1937.
21. Haggerty CL, Totten PA, Tang G, et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. *Sex Transm Infect* 2016; 92: 441–446.
22. Persson E, Bergstrom M, Larsson PG, et al. Infections after hysterectomy. A prospective nation-wide Swedish study. The Study Group on Infectious Diseases. *Acta Obstet Gynecol Scand* 1996; 75: 757–761.
23. Soper DE, Bump RC and Hurt WG. Bacterial vaginosis and trichomoniasis vaginitis are risk factors for cuff cellulitis after abdominal hysterectomy. *Am J Obstet Gynecol* 1990; 163: 1016–1021.
24. Charonis G and Larsson PG. Use of pH/whiff test or QuickVue advanced pH and Amines test for the diagnosis of bacterial vaginosis and prevention of postabortion pelvic inflammatory disease. *Acta Obstet Gynecol Scand* 2006; 85: 837–843.
25. Miller L, Thomas K, Hughes JP, et al. Randomised treatment trial of bacterial vaginosis to prevent post-abortion complication. *BJOG* 2004; 111: 982–988.
26. Lamont RF, Nhan-Chang CL, Sobel JD, et al. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. *Am J Obstet Gynecol* 2011; 205: 177–190.
27. Leitich H, Bodner-Adler B, Brunbauer M, et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. *Am J Obstet Gynecol* 2003; 189: 139–147.
28. Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. *Cochrane Database of Systematic Reviews* 2013, Issue 1. Art. No.: CD000262. DOI: 10.1002/14651858.CD000262.pub4.
29. Sorvillo F and Kernott P. *Trichomonas vaginalis* and amplification of HIV-1 transmission. *Lancet* 1998; 351: 213–214.
30. Laga M, Manoka A, Kivuvu M, et al. Non ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. *AIDS* 1993; 7: 95–102.
31. McClelland RS, Sangere L, Hassan WM et al. Infection with *Trichomonas vaginalis* increases the risk of HIV-1 acquisition. *J Infect Dis* 2007; 195: 698–702.
32. Tanton C, Weiss HA, Le Goff J et al. Correlates of HIV-1 genital shedding in Tanzanian women. *PLoS One* 2011; 6: e17480.
33. Mavedzenge SN, Pol BV, Cheng H et al. Epidemiological synergy of *Trichomonas vaginalis* and HIV in Zimbabwean and South African women. *Sex Transm Dis* 2010; 37: 460–466.
34. Cotch MF, Pastorek JG, Nugent RP, et al. *Trichomonas vaginalis* associated with low birth weight and preterm delivery. *Sex Transm Dis* 1997; 24: 353–360.
35. French JI, McGregor JA, Draper D, et al. Gestational bleeding, bacterial vaginosis, and common reproductive tract infections: risk for preterm birth and benefit of treatment. *Obstet Gynecol* 1999; 93: 715–724.
36. Gülmezoglu AM and Azhar M. Interventions for trichomoniasis in pregnancy. *Cochrane Database Syst Rev* 2011; 5: CD000220.
37. Donders GGG, Bellen G, Grinceviciene S, et al. The limited value of symptoms and signs in the diagnosis of vaginal infections. *Arch Intern Med* 1990; 150: 1929–1933.

38. Donders GG, Van CK, Bellen G, et al. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. *BJOG* 2009; 116: 1315–1324.
39. Roberts CL, Algert CS, Rickard KL, et al. Treatment of vaginal candidiasis for the prevention of preterm birth: a systematic review and meta-analysis. *Syst Rev* 2015; 4: 31.
40. Holzer I, Farr A, Hagmann M, et al. The colonization with *Candida* species is more harmful in the second trimester of pregnancy. *Arch Gynecol Obstet* 2017; 295: 891–895.
41. Abbott J. Clinical and microscopic diagnosis of vaginal yeast infection: a prospective analysis. *Ann Emerg Med* 1995; 25: 587–591.
42. Eckert LO, Hawes SE, Stevens CE, et al. Vulvovaginal candidosis: clinical manifestations, risk factors, management algorithm. *Obstet Gynecol* 1998; 92: 757–765.
43. Sonnex C and Lefort W. Microscopic features of vaginal candidosis and their relation to symptomatology. *Sex Transm Infect* 1999; 75: 417–419.
44. Mendling W, Brasch J, Cornely OA, et al. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding mucocutaneous candidosis). *Mycoses* 2015; 58: 1–15.
45. van de Wigert J, Altini L, Jones H, et al. Two methods of self-sampling compared to clinician sampling to detect reproductive tract infections in Gugulethu, South Africa. *Sex Transm Dis* 2006; 33: 516–523.
46. Nugent RP, Krohn MA and Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. *J Clin Microbiol* 1991; 29: 297–301.
47. Guédou FA, Van Damme L, Mirembe F, et al. Intermediate vaginal flora is associated with HIV prevalence as strongly as bacterial vaginosis in a cross-sectional study of participants screened for a randomised controlled trial. *Sex Transm Infect* 2012; 88: 545–551.
48. Ison CA and Hay PE. Validation of a simplified grading of gram stained vaginal smears for use in genitourinary medicine clinics. *Sex Transm Infect* 2002; 78: 413–415.
49. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. *Am J Med* 1983; 74: 14–22.
50. Gallo MF, Jamieson DJ, Cu US, et al. Accuracy of clinical diagnosis of bacterial vaginosis by human immunodeficiency virus infection status. *Sex Transm Dis* 2011; 38: 270–274.
51. Singh RH, Zenilman JM, Brown KM, et al. The role of physical examination in diagnosing common causes of vaginitis: a prospective study. *Sex Transm Infect* 2013; 89: 185–190.
52. Myziuk L, Romanowski B and Johnson SC. BVBlue test for diagnosis of bacterial vaginosis. *J Clin Microbiol* 2003; 41: 1925–1928.
53. Gaydos CA, Begaj S, Schwebke J et al. Clinical validation of a test for the diagnosis of vaginitis. *Obstet Gynecol* 2017; 130: 181–189.
54. Donders GG, Vereecken A, Bosmans E, et al. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. *BJOG* 2002; 109: 34–43.
55. Rumyantseva TA, Bellen G, Savochkina YA, et al. Diagnosis of aerobic vaginitis by quantitative real-time PCR. *Arch Gynecol Obstet* 2016; 294: 109–114.
56. Hopwood V, Crowley T, Horrocks CT, et al. Vaginal candidosis: relation between yeast counts and symptoms and clinical signs in non-pregnant women. *Genitourin Med* 1988; 64: 331–334.
57. Odds FC, Webster CE, Mayuranathan P, et al. *Candida* concentrations in the vagina and their association with signs and symptoms of vaginal candidosis. *J Med Mycol* 1988; 26: 277–283.
58. Priestley CJ, Jones BM, Dhar J, et al. What is normal vaginal flora? *Genitourin Med* 1997; 73: 23–28.
59. Kingston MA, Bansal D and Carlin EM. ‘Shelf life’ of *Trichomonas vaginalis*. *Int J STD AIDS* 2003; 14: 28–29.
60. Bickley LS, Krisher KK, Punsalang A, et al. Comparison of direct fluorescent antibody, acridine orange, wet mount and culture for detection of *Trichomonas vaginalis* in women attending a public sexually transmitted disease clinic. *Sex Transm Dis* 1989; 127–131.
61. Kreiger JN, Tam MR, Stevens CE, et al. Diagnosis of trichomoniasis: comparison of conventional wet-mount examination with cytological studies, cultures, and monoclonal antibody staining of direct specimens. *JAMA* 1988; 259: 1223–1227.
62. Nye MB, Schwebke JR and Body BA. Comparison of APTIMA *Trichomonas vaginalis* transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. *Am J Obstet Gynecol* 2009; 200: 188.e181–188.e187.
63. Hegazy MM, El-Tantawy NL, Soliman MM, et al. Performance of rapid immunochromatographic assay in the diagnosis of *Trichomoniasis vaginalis*. *Diagn Microbiol Infect Dis* 2012; 74: 49–53.
64. Campbell L, Woods V, Lloyd T, et al. Evaluation of the OSOM *Trichomonas* rapid test versus wet preparation examination for detection of *Trichomonas vaginalis* vaginitis in specimens from women with a low prevalence of infection. *J Clin Microbiol* 2008; 46: 3467–3469.
65. Borchardt KA, et al. A comparison of the sensitivity of the InPouch TV, diamond’s and trichosel media for detection of *Trichomonas vaginalis*. *Genitourin Med* 1997; 73: 297–298.
66. el Naga IF, Khalifa AM and el Azzouni MZ. In-pouch TV culture system in diagnosis of *Trichomonas vaginalis* infection. *J Egypt Soc Parasitol* 2001; 31: 647–656.
67. Levi MH, Torres J, Pina C, Klein RS. Comparison of the InPouch TV culture system and diamond’s modified medium for detection of *Trichomonas vaginalis*. *J Clin Microbiol* 1997; 35: 3308–3310.
68. Van Der Shee C, van Belkum A, Zwiggers L et al. Improved diagnosis of *Trichomonas vaginalis* infection by PCR using vaginal swabs and urine specimens

- compared to diagnosis by wet mount, culture and fluorescent staining. *J Clin Microbiol* 1999; 37: 4127–4130.
69. Radonjic IV, Dzamic AM, Mitrovic SM, et al. Diagnosis of *Trichomonas vaginalis*: the sensitivities and specificities of microscopy, culture and PCR assay. *Eur J Obstet Gynecol Reprod Biol* 2006; 126: 116–120.
70. Hardick A, Hardwick J, Wood BJ, Gaydos C. Comparison between the Gen-Probe transcription-mediated amplification *Trichomonas vaginalis* research assay and real-time PCR for *Trichomonas vaginalis* detection using a Roche LightCycler instrument with female self-obtained vaginal swab samples and male urine samples. *J Clin Microbiol* 2006; 44: 4197–4199.
71. Munson E, Napierala M, Olson R et al. Impact of *Trichomonas vaginalis* transcription-mediated amplification-based analyte-specific reagent testing in a metropolitan setting of high sexually transmitted disease prevalence. *J Clin Microbiol* 2008; 46: 3368–3374.
72. Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for *Trichomonas vaginalis* in women: results from a prospective U.S. clinical trial. *J Clin Microbiol* 2011; 49: 4106–4111.
73. Ginocchio CC, Chapin K, Smith JS, et al. Prevalence of *Trichomonas vaginalis* and coinfection with *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in the United States as determined by the Aptima *Trichomonas vaginalis* nucleic acid amplification assay. *J Clin Microbiol* 2012; 50: 2601–2608.
74. Larsson P-G. Treatment of bacterial vaginosis. *Int J STD AIDS* 1992; 3: 239–247.
75. Joesoef MR and Schmid GP. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. *Clin Infect Dis* 1995; 20: S72–S79.
76. Schwebke JR and Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for the treatment of symptomatic bacterial vaginosis. *Clin Infect Dis* 2007; 44: 213–219.
77. Bradshaw CS, Pirotta M, De GD, et al. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. *PLoS One* 2012; 7: e34540.
78. Weissenbacher ER, Donders G, Unzeitig V, et al. A comparison of dequalinium chloride vaginal tablets (Fluomizin) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. *Gynecol Obstet Invest* 2012; 73: 8–15.
79. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. *J Infect Dis* 2006; 193: 1478–1486.
80. Brotman RM, Klebanoff MA, Nansel TR et al. A longitudinal study of vaginal douching and bacterial vaginosis – a marginal structural modeling analysis. *Am J Epidemiol* 2008; 168: 188–196.
81. Bradshaw CS, Vodstrcil LA, Hocking JS et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. *Clin Infect Dis* 2013; 56: 777–786.
82. Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. *Am J Obstet Gynecol* 2006; 194: 1283–1289.
83. McClelland RS, Balkus JE, Lee J, et al. Randomised trial of periodic presumptive treatment with high dose intravaginal metronidazole and miconazole to prevent vaginal infections in HIV-negative women. *J Infect Dis* 2015; 211: 1875–1882.
84. McClelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. *J Infect Dis* 2008; 197: 1361–1368.
85. Andersch B, Lindell D, Dahlen I, et al. Bacterial vaginosis and the effect of intermittent prophylactic treatment with an acid lactate gel. *Gynecol Invest* 1990; 30: 114–119.
86. Senok AC, Verstraelen H, Temmerman M, et al. Probiotics for the treatment of bacterial vaginosis. *Cochrane Database Syst Rev* 2009; 4: CD006289.
87. Hanson L, VandeVusse L, Jerme M, et al. Probiotics for treatment and prevention of urogenital infections in women: a systematic review. *J Midwifery Womens Health* 2016; 61: 339–355.
88. Sobel JD, Reichman J, Misra D, et al. Prognosis and treatment of desquamative inflammatory vaginitis. *Obstet Gynecol* 2011; 117: 850–855.
89. Watson MC, Grimshaw JM, Bond CM, et al. Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. *BJOG* 2002; 109: 85–95.
90. Nurbhai M, Grimshaw J, Watson M, et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). *Cochrane Database Syst Rev* 2007; 4: CD002845.
91. Sobel JD, Kapernick PS, Zervos M, et al. Treatment of complicated *Candida* vaginitis: comparison of single and sequential doses of fluconazole. *Am J Obstet Gynecol* 2001; 185: 363–369.
92. Mendling W and Schlegelmilch R. Three-day combination treatment for vulvovaginal candidosis with 200 mg clotrimazole vaginal suppositories and clotrimazole cream for the vulva is significantly better than treatment with vaginal suppositories alone – an earlier, multi-centre, Placebo-Controlled Double Blind Study. *Geburtsh Frauenheilk* 2014; 74: 355–360.
93. Sobel J, Wiesenfeld H, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. *N Engl J Med* 2004; 351: 876–883.
94. Cooke G, Watson C, Smith J, et al. Treatment for recurrent vulvovaginal candidiasis (thrush). *Cochrane Database Syst Rev* 2011; 5: CD009151.
95. Donders G, Bellen G, Byttebier G et al. Individualized decreasing-dose maintenance fluconazole regimen for

- recurrent vulvovaginal candidiasis (ReCiDiF trial). *Am J Obstet Gynecol* 2008; 199: 613–619.
96. Rosa MI, Silva BR, Pires PS et al. Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol* 2013; 167: 132–136.
  97. Nyirjesy P, Zhao Davies S, Johnson E, et al. How to treat persistent vaginal yeast infection due to species other than *Candida albicans*. *Sex Transm Infect* 2013; 89: 165–166.
  98. Dennerstein GJ. Depo-Provera in the treatment of recurrent vulvovaginal candidiasis. *J Reprod Med* 1986; 31: 801–803.
  99. Forna F and Gülmezoglu AM. Interventions for treating trichomoniasis in women. *Cochrane Database Syst Rev* 2003; 2: CD000218.
  100. Thin RN, Symonds MAE, Booker R, et al. Double-blind comparison of a single dose and a five-day course of metronidazole in the treatment of trichomoniasis. *Br J Vener Dis* 1979; 55: 354–356.
  101. Howe K and Kissinger PJ. Single-dose compared with multidose metronidazole for the treatment of trichomoniasis in women: a meta-analysis. *Sex Transm Dis* 2017; 44: 30–35.
  102. Pearlman MD, Yashar C, Ernst S, et al. An incremental dosing protocol for women with severe vaginal trichomoniasis and adverse reactions to metronidazole. *Am J Obstet Gynecol* 1996; 174: 934–936.
  103. Kurohara ML, Kwong FK, Lebherz TB, et al. Metronidazole hypersensitivity and oral desensitization. *J Allergy Clin Immunol* 1991; 88: 279–280.
  104. Das S, Huengsborg M and Shahmanesh M. Treatment failure of vaginal trichomoniasis in clinical practice. *Int J STD AIDS* 2005; 16: 284–286.
  105. Bosserman EA, Helms DJ, Mosure DJ, et al. Utility of antimicrobial susceptibility testing in *Trichomonas vaginalis*-infected women with clinical treatment failure. *Sex Transm Dis* 2011; 38: 983–987.
  106. Sobel JD, Nyirjesy P and Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. *Clin Infect Dis* 2001; 33: 1341–1346.
  107. Mammen-Tobin A and Wilson JD. Management of metronidazole-resistant *Trichomonas vaginalis* – a new approach. *Int J STD AIDS* 2005; 16: 488–490.
  108. Muanda FT, Sheehy O and Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. *CMAJ* 2017; 189: E625–E633.
  109. Gülmezoglu AM and Azhar M. Interventions for trichomoniasis in pregnancy. *Cochrane Database Syst Rev* 2011; 5: CD000220.
  110. Czeizel AE and Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. *BJOG* 1998; 105: 322–327.
  111. Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. *Am J Obstet Gynecol* 1995; 172: 525–529.
  112. Caro-Paton T, Carvajal A, de Diego IM, et al. Is metronidazole teratogenic: a meta-analysis. *Br J Clin Pharmacol* 1997; 44: 179–182.
  113. Molgaard-Nielsen D, Pasternak B and Hviid A. Use of fluconazole during pregnancy and risk of birth defects. *N Engl J Med* 2013; 369: 830–839.
  114. Mølgard-Nielsen D, Svanström H, Melbye M, et al. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. *JAMA* 2016; 315: 58–67.
  115. Amaya-Guio J, Viveros-Carreño DA, Sierra-Barrios EM, et al. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. *Cochrane Database Syst Rev* 2016; 10: CD011701.
  116. Bisschop MP, Merkus JM, Scheygrond H, et al. Co-treatment of the male partner in vaginal candidosis: a double-blind randomized control study. *BJOG* 1986; 93: 79–81.
  117. Fong IW. The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. *Genitourin Med* 1992; 68: 174–176.
  118. Lyng J and Christensen J. A double blind study of treatment with a single dose tinidazole of partners to females with trichomoniasis. *Acta Obstet Gynecol Scand* 1981; 60: 199–201.
  119. Schwebke JR and Desmond RA. A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. *Sex Transm Dis* 2010; 37: 392–396.

## Appendix I

### Review of the literature

An extensive literature review was performed using Medline for the years 2009–2017. MEDLINE search-keywords: vulvovaginal candidosis, vaginal candidosis, vaginal candida, *Trichomonas vaginalis*, trichomoniasis, Bacterial vaginosis, non-specific vaginitis, abnormal vaginal flora, vaginal dysbiosis. The resulting articles were handsearched and sorted. Further references were obtained from these articles.

The Cochrane Library was searched; search-keywords were:

vulvovaginal candidosis, vaginal candidosis, vaginal candida, *Trichomonas vaginalis*, in women, bacterial vaginosis.

The 2015 US CDC guidelines for the treatment of Sexually Transmitted Diseases and the related UK national guidelines ([www.bashh.org](http://www.bashh.org)) were reviewed.

Tables of levels of evidence and grading of recommendations:

(see <http://www.iusti.org/regions/Europe/pdf/2017/ProtocolForProduction2017.pdf>).

## Appendix 2. Declarations of interests

Jackie Sherrard: JS has received consultancy fees from Becton Dickinson

Janet Wilson: JW has received speaker fees from BD Diagnostics; unconditional research grants in the form

of diagnostic tests from Hologic; and remuneration for contract research from Starpharma.

Gilbert Donders: received consultancy fees and/or speakers fees from Medinova, Alfa-Wasserman, Bayer, Phacobel and GSK.

Werner Mendling: WM declares in the last three years royalties by Aristo Pharma GmbH Berlin, Dr August Wolff GmbH & Co. KG Arzneimittel Bielefeld, Dr Kade Pharmazeutische Fabrik GmbH

Berlin, Pierre Fabre Pharma GmbH Freiburg, SymbioPharm Herborn and Johnson & Johnson GmbH Neuss (all Germany), and Medinova AG Zurich/Switzerland

Jørgen S Jensen: JSJ has received speaker fees from Hologic and SSI has received remuneration for contract research from Hologic, SpeedX, NYtor, Diagenode, Nabriva, Angelini, GSK, and Osel